EUVIMEDEUVIMED entdecken
Crossref

Chemokine‑ and chemokine receptor-based subtypes predict prognosis, immunotherapy and chemotherapy response in colorectal cancer patients

Wenjie Zhu, Shimin Zhao, Xiufeng Cheng, Changlei Wu, Zitao Liu, Jun Huang

International Immunopharmacology · 2024

DOI: 10.1016/j.intimp.2024.112172 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Immunopharmacology, 2024. Verfasst von Wenjie Zhu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastrointestinal Surgery, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi Province, Chi…. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Immunotherapy, Chemokines, Receptors, Chemokine. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 59 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Jiangxi Provincial Natural Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: The clinical significance and comprehensive characteristics of chemokines and chemokine receptors in colorectal cancer (CRC) have not been previously reported. Our study aims to investigate the expression profiles of chemokines and chemokine receptors, as well as establish subtypes in CRC. METHODS: 1009 CRC samples were enrolled in our study. Consensus unsupervised clustering analysis was conducted to establish subtypes, and a risk score model was developed using univariate Cox regression and least absolute shrinkage and selection operator (LASSO) analyses. 36 pairs of tissue specimens of CRC patients and two CRC cell lines were used to validate the subtypes and risk score in vitro. Quantitative real-time PCR and western blotting were employed to validate mRNA and protein expression levels, respectively. Flow cytometry was utilized for analyzing cell apoptosis, while cell viability assay and EdU assay were conducted to assess cell proliferation ability. RESULTS: The Cluster B group shares similarities with the low-risk group in terms of exhibiting a higher level of immune cell infiltration and belonging to hot tumor. Patients CRC in the Cluster B group demonstrate a more favorable prognosis and exhibit better response to immunotherapy and chemotherapy. On the other hand, the Cluster A group resembles the high-risk group as it displays lower levels of immune cell infiltration, indicating a cold tumor phenotype. CRC patients in the Cluster A group have poorer prognoses and show less therapeutic efficacy towards immunotherapy and chemotherapy. Furthermore, we utilized a total of 36 pairs of tissue samples obtained from patients with CRC, along with two CRC cell lines for validation in vitro. This comprehensive approach further enhances the scientific validity and reliability of the identified subtypes and risk score in their ability to predict prognosis, response to immunotherapy, and response to chemotherapy among CRC patients. CONCLUSION: We first established robust prognostic subtypes based on chemokines and chemokine receptors, which could potentially serve as a novel biomarker for guiding individualized treatment in patients with CRC undergoing immunotherapy and chemotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsImmunotherapyChemokinesReceptors, ChemokineHumansPrognosisFemaleMaleMiddle AgedBiomarkers, TumorCell Line, TumorAgedGene Expression Regulation, NeoplasticAntineoplastic AgentsCell ProliferationApoptosis

Stichwörter der Autor:innen

ChemokineChemotherapyColorectal cancerImmunotherapySubtype

Substanzen

ChemokinesReceptors, ChemokineBiomarkers, TumorAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Gastrointestinal Surgery, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi Province, China; Jiangxi Province Key Laboratory of Molecular Medicine, The Second…
  • Department of Critical Care Medicine, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi Province, China.
  • Department of Gastrointestinal Surgery, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi Province, China. Electronic address: Huangjun0727@163.com.

Förderung

  • National Natural Science Foundation of China
  • Jiangxi Provincial Natural Science Foundation

Zitieren

APA

Zhu, W., Zhao, S., Cheng, X., Wu, C., Liu, Z., & Huang, J. (2024). Chemokine‑ and chemokine receptor-based subtypes predict prognosis, immunotherapy and chemotherapy response in colorectal cancer patients. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2024.112172

Vancouver

Zhu W, Zhao S, Cheng X, Wu C, Liu Z, Huang J. Chemokine‑ and chemokine receptor-based subtypes predict prognosis, immunotherapy and chemotherapy response in colorectal cancer patients. International Immunopharmacology. 2024. doi:10.1016/j.intimp.2024.112172

BibTeX
@article{Zhu2024,
  author = {Zhu, Wenjie and Zhao, Shimin and Cheng, Xiufeng and Wu, Changlei and Liu, Zitao and Huang, Jun},
  title = {Chemokine‑ and chemokine receptor-based subtypes predict prognosis, immunotherapy and chemotherapy response in colorectal cancer patients},
  journal = {International Immunopharmacology},
  year = {2024},
  doi = {10.1016/j.intimp.2024.112172}
}
Kostenlos starten →